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Oral Iloprost in the Treatment of Thromboangiitis Obliterans (Buerger's 
Disease): a Double-blind, Randomised, Placebo-controlled Trial 
The European TAO Study Group 
Objectives: To assess efficacy and tolerability of two dosages of the oral prostacyclin analogue iloprost versus placebo in 
thromboangiitis obliterans (TAO). 
Design: Placebo-controlled, double-blind, study; TAO patients randomised to iloprost 100, 200 pg, or placebo bid for 8 
weeks, with 6 months' follow-up. 
Methods: Three-hundred and nineteen TAO patients with rest pain, trophic lesions (or both)from 23 clinics in six 
European countries. Primary endpoint: total healing of most important lesion. Secondary endpoint: relief of rest pain 
without need of analgesics. Combined endpoint: alive without major amputation, no lesions, no rest pain, no use of 
analgesics. 
Results: Total healing of lesions was not significantly different between treatment groups at any time point. For relief 
of rest pain without need of analgesics, low dose (LD) iloprost was significantly more effective than placebo at end of 
follow-up (placebo 49%; LD iloprost 63%; p=O.020). This also applied to the combined endpoint (placebo 35%; LD 
iloprost 50%; p = 0.016). High dose iloprost (HD) failed to show significant reatment effects over placebo. 
Conclusions: Iloprost LD was significantly more effective than placebo for relief of rest pain without need of analgesics 
and for a combined endpoint, at 6 months of follow-up, whilst both iloprost doses howed no significant effects vs. placebo 
on total healing of lesions. 
Key Words: Thromboangiitis obliterans (TAO, Buerger's disease); Trophic lesions; Ischaemic rest pain; Iloprost; Efficacy; 
Safety. 
Introduction 
Thromboangiitis obliterans (TAO), also known as 
Buerger's disease, is a non-atherosclerotic n- 
flammatory obliterative disease of the small and 
medium sized arteries. 1-6 This disease occurs pre- 
dominantly in young Caucasian men who are heavy 
smokers ~-6 but all races and both sexes can present 
with  TAO. 4-6 
Cessation of smoking is the most important step 
in the management of TAO. 2'4-4 There is much un- 
certainty on the efficacy of the numerous drugs (vaso- 
dilating agents, anticoagulants, non-steroidal anti- 
inflammatory drugs) assessed in the treatment of this 
disorder. ~4 Calcium channel blockers have occasion- 
ally been reported to reduce both the frequency and 
severity of Raynaud attacks in TAO patients. 1 How- 
ever, no placebo-controlled, double-blind studies have 
been performed with these drugs. 
The most promising drug treatment to improve 
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symptoms in these patients has been iloprost, a prosta- 
cyclin analogue that stimulates blood flow and has 
vasodilatory and platelet inhibitory action. 15 In a pre- 
vious double-blind trial, 133 patients with TAO were 
randomly selected to receive either intravenous ilo- 
prost or aspirin. 7Analysis howed that 63% of patients 
treated with iloprost were entirely free of ischaemic 
rest pain, compared with 28% of patients treated with 
aspirin at the end of the 28-day treatment period 
(p<0.05 in favour of iloprost). Also, ischaemic ulcers 
healed completely in 35% of the study group, com- 
pared with only 13% in the control group. At 6 months, 
the overall response rate (combined pain relief and/ 
or ulcer healing) was 88% in the group given iloprost 
vs. 21% in the group given aspirin (p<0.05 in favour 
of iloprost). 
A major drawback to intravenous use of iloprost 
is the need for hospitalisation of patients. An oral 
formulation of iloprost (iloprost clathrate xtended- 
release capsules) has now been developed, which 
would allow treatment on an outpatient basis and for 
longer periods of time. Studies in human volunteers s 
and in patients with either peripheral atherosclerosis 9 
or TAO 1° have demonstrated that doses from 50 gg up 
to 200 gg taken twice daily show an acceptable safety 
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and tolerability profile. The aim of the present rial 
was to investigate the effectiveness of oral iloprost in 
the treatment of TAO patients with rest pain with or 
without trophic lesions. 
Materials and Methods 
The trial was a randomised, placebo-controlled, 
double-blind study conducted in 22 centres in six 
countries: Bulgaria, Poland, Portugal, Greece, France 
and Israel (see appendix for list of investigators). 
Patients 
To be considered for the trial, patients had to fulfil all 
of the following criteria: age under 50 years, current 
smoker or history of smoking, angiographic criteria 
compatible with TAO with typical arteriographic find- 
ings, e.g. skip lesions below the popliteal artery and/ 
or corkscrew collaterals (Martorell's sign) or direct 
collaterals below the knee in the absence of ath- 
erosclerotic lesions (based on an aortoarteriogram 
which had to be performed within 5 years before entry 
into the trial) and current or history of superficial 
thrombophlebitis or vasospastic symptoms. 
Patients were excluded from the study if they had 
diabetes mellitus, treated or untreated hypertension 
(systolic BP>160 mmHg/diastolic BP>95 mmHg), 
hypercholesterolaemia (>260 mg/dl), atrial fibrillation 
(or other known causes of arterial embolism) and 
sympathectomy within the last 3 weeks of entering 
the study. Oral anticoagulants had to be stopped 1 
week before randomisation. Additionally, all TAO 
patients had to have rest pain, ischaemic lesions of the 
extremities, (or both) of sufficient severity to require 
hospitalisation and specific treatment. 
Randomisation a d drug administration 
Patients satisfying the criteria for selection and who 
gave their written informed consent were randomly 
assigned to one of three treatment groups: 200 gg 
iloprost per day, 400 gg iloprost per day, or matching 
placebo. The iloprost capsules contained either 50 gg 
or 100 #g iloprost and were taken twice daily, in the 
morning and afternoon, for 8 weeks. The interval 
between the morning and afternoon dose was 5 h. 
On day 1, all patients received one capsule twice 
daily (100 gg iloprost per day, 200 gg iloprost per day 
or placebo). From day 2 onwards patients had to take 
two capsules of their medication twice daily (200 gg 
iloprost per day, 400 gg iloprost per day or placebo). 
Apart from the lower dose on day 1 a change of 
dosage was not permitted uring the trial. In case of 
intolerance to the trial medication during the first 4 
days of treatment, study medication was discontinued 
and the patient was withdrawn from this study and 
transferred to a complementary open trial. 
During the 8-week treatment period the use of drugs 
aimed for the treatment of TAO (e.g. aspirin, pen- 
toxiphylline, naftidrofuryl, dextran, loftyl), as well as 
intravenous heparin and oral anticoagulants were not 
permitted. Drugs for the treatment of concomitant 
diseases, ubcutaneous heparin, local wound and limb 
care (including local debridement or amputation), anti- 
biotics and physical procedures (e.g. positional ex- 
ercise, slow walking, body heating, hyperbaric oxygen) 
were permitted. 
Treatment phase and follow-up 
Patients were hospitalised at least during the first 
week of treatment. Blood pressure and heart rate were 
measured hourly for 4 h after each administration of
medication. At the end of week 1 the patients could 
be discharged from the hospital and continue the trial 
as out-patients but had to return on weeks 2, 4 and 6 
for a clinic visit. At the end of week 8 (end of treatment), 
a closing examination and the assessments scheduled 
for this visit were performed and documented. The 
following variables were evaluated at each visit: num- 
ber of trophic lesions and healing of the most important 
lesion determined atbaseline, assessment of rest pain 
and consumption of analgesics, blood pressure and 
heart rate, Doppler pressures, ECG, haematology, 
thromboplastin a d prothrombin times, clinical chem- 
istry and urine dipstick, smoking habits, superficial 
thrombophlebitis and vasospastic symptoms (Ray- 
naud phenomenon), blood sampling for compliance 
check, adverse vents, concomitant medication, as well 
as interventions, including major and minor am- 
putations and revascularisations. This examination 
had to be carried out for all patients who had been 
randomised, even if the study drug was terminated 
prematurely. 
After the end of treatment, patients were followed 
up for a further 6 months. Examinations were per- 
formed after 1 month, 3 months, and 6 months. 
Endpoints 
Primary efficacy endpoint was the number of patients 
with total healing of the trophic lesion judged as most 
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important by the investigator at baseline (ulcer or 
gangrene/necrosis). The most important lesion was 
regarded as healed only if the physician's assessment 
was graded as "totally healed". 
The two following endpoints were applicable to 
all patients: secondary endpoint was the number of 
patients with relief of rest pain without need for 
analgesics in patients with rest pain at baseline. A 
patient was totally relieved of rest pain if the intensity 
of rest pain was judged as "no pain" and no analgesics 
were used. 
A combined endpoint, including the two major 
symptoms of TAO, i.e. trophic lesions and rest pain, 
as well as major amputations (above the ankle), was 
added before unblinding the treatment code. It was 
defined as the number of patients alive without major 
amputation, o lesions, no rest pain and no analgesics. 
input as non-healing. Due to the multiple comparisons 
of the two iloprost groups and placebo, a Bonferroni 
correction of the type I error of significance (~) was 
applied. The corrected ~ was 0.025. The analysis was 
based on the "intent-to-treat" population (ITT) for 
patients with lesions at baseline. 
The same strategy has been used for the secondary 
efficacy endpoint, the number of patients with total 
relief of rest pain without need for analgesics for 
patients with rest pain at baseline. Additional variables 
for efficacy were analysed using a Mantel-Haenszel 
test for dichotomous variables or an extended Mantel- 
Haenszel test with modified ridit scores for ordinal 
parameters. Country was used as strata. Laboratory 
data were classified as normal, abnormal or markedly 
abnormal. Adverse events were rated as mild, mod- 
erate or severe. 
Ethical procedures 
The trial was conducted in accordance with the De- 
claration of Helsinki and the European Good Clinical 
Practice (GCP) Guidelines. Study approval by the local 
ethical committees was obtained in each centre. 
Statistical methods and data handling 
Assuming a lesion healing rate of 10% for placebo, 77 
patients per group were necessary todetect adifference 
of D--20% with a type I error probability of ~ = 0.05 
(one-sided) and a test power of lq3=0.90. With the 
assumption of about 80% of patients with lesions, a 
group size of 100 patients would guarantee the given 
test power. An a-adjustment according to Bonferroni 
(two comparisons vs. placebo at a test level of ~/2 = 
0.025 each) with 77 patients per group increases the 
detectable difference to D = 22%. A drop out ratio of 
up to 40% was assumed, and therefore 140 patients 
were to be included per treatment group. 
Data entry and statistical analysis were done by 
Biodat, Berlin. An "intent-to-treat" (ITT) analysis com- 
prising all randomised patients with post-treatment 
data was carried out. The time point for statistical tests 
for all endpoints was at the end of 6 months of follow- 
up. 
To analyse the drug effect on the primary endpoint 
total healing of the most important lesion at end 
of follow-up, a one-sided Mantel-Haenszel test with 
stratification adjustment for countries was used. Miss- 
ing information on the most important lesion was 
Sadety 
An adverse vent (AE) was defined as any undesirable 
event, including unfavourable changes of existing or 
development of new concomitant diseases compared 
with baseline, occurring in a patient during a clinical 
trial, whether or not considered related to the in- 
vestigational product. Intensity of AEs was rated as 
mild, moderate or severe. Adverse events were clas- 
sified as serious or non-serious. A serious AE (SAE) 
was defined as any AE that was life-threatening or
fatal, permanently disabling, resulted in congenital 
anomaly or cancer, or necessitated inpatient hos- 
pitalisation or prolongation of existing inpatient hos- 
pitalisation. 
Patients transferred from this double-blind trial to 
the open study were reported as drop-outs from the 
main study. 
Results 
The Steering Committee of the European Study Group 
on TAO met at 28 months after the start of the trial to 
discuss the blinded results of the trial. The drop-out 
rate was only 10% compared with the estimated/ 
expected rop-out rate of 40% when the protocol was 
drafted. While maintaining the other assumptions to
calculate the number of patients required, it appeared 
that only 100 patients were required in each treatment 
group instead of 140. At that time 319 patients were 
randomised and further ecruitment was stopped. All 
319 randomised patients received medication at least 
once and were evaluated in the ITT analysis (Table 1). 
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Table 1. Patient disposition.* 
Placebo Low-dose High-dose Total 
iloprost iloprost 
Patients admitted 103 
Evaluable cases 103 
Completed casest 96 
Transferred cases 1 




adverse vents 2 
other reason 1 
Follow-up not completed:~ 7 
Reason: 
lost to follow-up 2 
missing and others 5 
106 110 319 
(100) 106 (100) 110 (100) 319 
(93) 96 (91) 92 (84) 284 
0 5 6 
7 16 26 
1 2 3 
0 1 1 
1 6 9 
5 7 13 
6 9 22 
2 2 6 
4 7 16 
(100) 
(89) 
* Number of patients (percentages) are given. 
t 8 weeks' treatment and 6 months follow-up completed. 
{ 13 patients discontinued treatment and did not complete follow-up. 
Table 2. Characteristics of patients at randomisation to treatment with low-dose or high-dose oral iloprost or placebo. 
Placebo Low-dose iloprost High-dose Total 
(n = 103) (n = 106) iloprost (n = 319) 
(n=110) 
Age (years) [median (range)] 40 (18-50) 41 (18-50) 40 (19-53) 41 (18-53) 
No. (%) male 98 (95) 94 (89) 100 (91) 292 (92) 
Ethnic group [no. (%)] caucasian/white 99 (96) 103 (97) 108 (98) 310 (97) 
Smoking habits [no. (%)] 
smoker 53 (52) 52 (49) 56 (51) 161 (51) 
ex-smoker 50 (49) 54 (51) 54 (49) 158 (50) 
Duration of TAO (years) [median (range)[ 6.5 (0.1-23.9) 6.0 (0.1-22.2) 6.2 (0.1-23.5) 6.2 (0.1-23.9) 
Characteristic arteriographic findings [no. (%)] 102 (99) 106 (100) 110 (100) 318 (99) 
Reconstructive ascular surgery [no. (%)] 7 (7) 2 (2) 12 (11) 21 (7) 
Amputation [no. (%)] 
minor 21 (20) 29 (27) 26 (24) 76 (24) 
major 11 (11) 9 (9) 6 (6) 26 (8) 
Lumbar sympathectomy [no. (%)] 43 (42) 44 (42) 41 (37) 128 (40) 
Patients with [no. (%)] trophic lesions 70 (68) 63 (59) 65 (59) 198 (62) 
ulcer(s) 44 (64) 43 (68) 48 (74) 135 (69) 
gangrene 25 (36) 20 (32) 17 (26) 62 (32) 
Patients with rest pain [no. (%)] 
none 1 (1) 1 (1) 2 (2) 4 (1) 
mild 34 (33) 38 (36) 32 (29) 104 (33) 
moderate 42 (41) 45 (43) 52 (47) 139 (44) 
severe 26 (25) 22 (21) 24 (22) 72 (23) 
Ankle brachial index (ABI) mean (s) 0.82 (0.31) 0.84 (0.27) 0.82 (0.32) 
Characteristics ofthe patient population at randomisation 
(Table 2) 
Overall the characteristics of patients in the three 
groups were similar at the time of randomisation. 
Sixty-two per cent of patients presented with trophic 
lesions (69% ulcers, 32% gangrene). In these 198 
patients, the most important lesion was on the toe in 
over 70% of patients, and on the forefoot in 15%. 
Almost all patients (315 out of 319) had rest pain at 
randomisation. There was some imbalance between 
groups regarding reconstructive ascular surgery at 
baseline, which was markedly lower in the low-dose 
iloprost group compared to the other groups. How- 
ever, the power of the study was too small to detect 
differences of this size. 
Efficacy results (Table 3) 
At the end of treatment (8weeks) the percentages of
patients with total healing of the most important 
lesion, which was the primary end point, were not 
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Table 3. Efficacy endpoints. Results of intent-to-treat (ITT) analysis. Number of patients and percentages are given. 
Placebo Low-dose High-dose 
iloprost iloprost 
Primary endpoint 
Total healing of most important trophic lesion 
week 8/end of treatment 
month 6/end of follow-up 
Secondary endpoint 
Total relief of rest pain without analgesics 
week 8/end of treatment 
month 6/end of follow-up 
12/70 (17) 12/63 (19) 10/65 (15) 
p = 0.406 vs placebo p = 0.590 vs. placebo 
29/70 (41) 31/63 (49) 27/65 (42) 
p=0.223 vs. placebo p=0.521 vs. placebo 
35/102 (34) 41/105 (30) 41/108 (38) 
p = 0.208 vs. placebo p = 0.269 vs. placebo 
50/102 (49) 66/105 (63) 53/108 (49) 
p = 0.020 vs. placebo p =0.604 vs. placebo 
Combined endpoint 
Alive without major amputation, nolesion, no rest 
pain, no analgesics 
week 8/end of treatment 
month 6/end of follow-up 
19/102 (19) 30/100 (30) 26/96 (27) 
p=0.032 vs. placebo p=0.088 vs. placebo 
34/96 (35) 50/100 (50) 40/102 (39) 
p=0.016 vs. placebo p=0.279 vs. placebo 
significantly different for either iloprost group com- 
pared to placebo (placebo 17%, low-dose iloprost 19%, 
high-dose iloprost 15%). Six months after the end of 
treatment, 41% of the patients in the placebo group, 
49% of the patients on low-dose iloprost, and 42% of 
patients on high-dose iloprost had attained total heal- 
ing of their most important lesion. Differences between 
groups were not statistically significant. 
For total relief of rest pain without analgesics the 
difference between groups at the end of treatment (8 
weeks) were not significant (placebo 34%, low-dose 
iloprost 39%, high dose iloprost 38%; p=0.208 and 
0.269 for the low and high dose of iloprost vs. placebo). 
At the end of follow-up total relief of rest pain without 
analgesics was attained by a significantly higher per- 
centage of patients on low-dose iloprost (63%) com- 
pared to placebo (49%; p = 0.020), while there was no 
significant difference of percentages of patients who 
were completely pain-free between high-dose iloprost 
(49%) and placebo. 
The combined end point (alive without major am- 
putation, no lesion, no rest pain, no analgesics) was 
attained by 19% of patients in the placebo group, 30% 
of patients in the low-dose iloprost group (p = 0.032 
vs. placebo) and by 27% of patients in the high- 
dose group (p=0.088 vs. placebo), at week 8/end of 
treatment. At month 6/end of follow-up 15% more 
patients on low-dose iloprost han on placebo attained 
the combined endpoint (p = 0.016), while the difference 
between high-dose iloprost and placebo was only 4% 
in favour of iloprost (Table 3). 
Healing of all trophic lesions was comparable in the 
three treatment groups. No differences were observed 
between the treatment groups in the incidence of 
vasospastic symptoms, superficial thrombophlebitis 
and Doppler pressures. 
Some additional analyses of the data were carried 
out for hypothesis generation. The two best scores of 
the six-point classification for assessment of healing 
of the most important lesion, namely total healing or 
lesion becoming smaller with granulation at base, were 
analysed as improved healing and explorative p-values 
calculated. The percentage of patients with improved 
healing of the most important lesion were as follows: 
at week 8/end of treatment placebo 40%, low-dose 
iloprost 55% (p = 0.056 vs. placebo), high-dose iloprost 
63% (p =0.008 vs. placebo). The corresponding per- 
centages at month 6/end of follow-up were: placebo 
62%, low-dose iloprast 84% (p=0.007 vs. placebo), 
high-dose iloprost 68% (p = 0.297 vs. placebo). 
Compl iance  
Blood samples to determine compliance were taken 
from 30 min to up to 5 h after dosing of the trial 
medication during week 1, 2, 4, 6 and 8. After treatment 
with low-dose iloprost, mean plasma levels in the 
dosing interval accounted for 83-159 pg/ml, and high- 
dose intake led to iloprost levels of 104-242 pg/ml. 
Adverse  events  
The overall incidence rate of adverse events during 
the treatment phase was for the high-dose iloprost 
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group about 25% higher (68%) compared with the 
low-dose iloprost group (43%) and the placebo group 
(38%). The most frequent AEs (more than 20%) in- 
cluded headache, followed by vasodilation and tris- 
mus (the latter two only for the high-dose iloprost 
group). Furthermore, 11% of patients on high-dose 
iloprost suffered from nausea. Other AEs were rare, 
with an incidence of less than 5%. During follow- 
up the incidence rate decreased in each of the three 
treatment groups to less than 15% (low-dose iloprost 
4%, high-dose iloprost 14%, placebo 7%). The intensity 
of the different events was rated as mild or moderate 
for the majority of events. Severe adverse vents were 
mainly headaches and vasodilatation i  the high-dose 
iloprost group (14 and 8 patients, respectively). 
Serious adverse vents (SAEs) were reported for 49 
patients during the study (15 on low-dose iloprost, 15 
on high-dose iloprost, 19 on placebo). No deaths were 
reported. The majority of SAEs reported uring the 
whole study were related to a lack of drug effect, 
requiring hospitalization for amputation or other sur- 
gical interventions, mainly sympathectomy (11on low- 
dose iloprost, 13 on high-close iloprost, 15 on placebo). 
The frequency of major amputations was low. During 
treatment or follow-up major amputations were car- 
ried out in 9/103 (9%) of patients on placebo and 5/ 
106 (5%) and 4/110 (4%) of patients on low and high 
dose of iloprost respectively. One patient on low-dose 
iloprost developed elevated liver enzymes after 4-8 
weeks of treatment, hat were still elevated after 6 
months of follow-up. 
Discussion 
Thromboangiitis obliterans i more common in Eastern 
Europe and Mediterranean countries than in Central 
Europe where, for unknown reasons, the incidence of 
the disease has declined considerably in the past 30 
years. 5 To recruit enough patients in an acceptable 
time period, medical centres in Poland, Bulgaria and 
Greece joined vascular centres in Central Europe, to 
conduct he largest double-blind trial in TAO patients 
ever published. 
No single symptom, sign or test is definitive for 
TAO. Therefore, the diagnosis of TAO in this study 
was based on a combination of clinical findings, viz. 
early start of symptoms (before 40 years of age), history 
of smoking or actual smokers, history or present su- 
perficial thrombophlebitis or of vasospastic problems, 
rest pain or serious ischaemic lesions on fingers or 
toes; all of these criteria had to be fulfilled in addition 
to typical angiographic findings (see also Patients and 
Methods section). To avoid recruiting patients with 
the combination of TAO and atherosclerosis; diabetes 
mellitus, hypertension, hypercholesterolaemia and or- 
ganic heart disease were among the exlusion criteria. 
Also, those with clinical and biological evidence of 
connective tissue disease could not enter the trial in 
order to avoid patients with vasculitis or suspected 
vascu!itis. 
As shown in Table 2, the study population consisted 
of 92% of males with a median age of 40 years in 
whom the diagnosis of TAO was established 6 years 
earlier, although symptoms occurred much earlier. 
All but one of the 319 randomised patients met the 
stringent clinical and arteriographic criteria requested 
in the protocol. Sixty-one percent of the patients' doc- 
uments including arteriograms were checked by ex- 
perts independent of the sponsor. About 64% of 
patients had superficial thrombophlebitis (acute or by 
history) with a predilection for the small veins of the 
foot or ankle (migratory phlebitis) or/and a va- 
sospastic syndrome (42%). As expected, s re- 
constructive surgery had been attempted in only 7% 
of the patients due to the diffuse distal character of 
the disease with no run-off vessels for a bypass graft. 
With a 24% minor and 8% major amputation rate 
before randomisation, the study population can be 
considered to have a serious degree of TAO. The 
incidence of these various findings corresponds very 
well with those reported in recent papers. 1-3'5't3 
The primary endpoint was total healing of the most 
important lesion at 6 months follow-up. The data show 
that total healing of trophic lesions is a slow process 
and is difficult to attain and sustain in TAO patients, 
if significant vascular occlusions are present. After 8 
weeks of treatment, less than 20% of the patients 
attained total healing of their most important lesion. 
No significant reatment effects of iloprost could be 
demonstrated. However, for improved healing of the 
most important lesion, defined as total healing or the 
lesion becoming smaller with granulation at base, 
dose-dependent treatment effects could be dem- 
onstrated for the low- and high-dose of iloprost after 
8 weeks of treatment, (high-dose iloprost vs. placebo, 
p = 0.008). At month 6/end of follow-up the treatment 
effect of low-dose iloprost vs. placebo had increased 
(p = 0.007), whilst only a small treatment effect of high- 
dose iloprost vs. placebo was observed (p=0.297). 
However, improved healing was not a prospectively 
defined end point, and these data can therefore only 
be interpreted as suggestive ofan effect of oral iloprost 
to promote lesion healing. 
During the study period about 50% of patients 
continued smoking, and the real percentage in these 
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outpatients of the current rial might have been even 
higher. In the trial with intravenous iloprost in hos- 
pitalized patients 80% of patients were reported to 
have stopped smoking7 TAO patients with comparable 
severity, but with at least 50% remaining smokers 
might explain the modest reatment effects of iloprost 
in this trial, particularly to achieve total healing of the 
most important lesion. 
Some results of this trial with oral iloprost are at 
variance with those obtained in an earlier study with 
intravenous iloprost (up to 2 ng/kg/min for 6 h /day 
for up to 28 days). 7The response rate in total healing 
in the present trial with oral low-dose iloprost or with 
placebo were respectively lower (19%), and higher 
(17%), when compared with the double-blind trial in 
TAO patients with intravenous iloprost. 7In both trials 
significantly more patients vs. placebo or aspirin, 
treated with respectively intravenous or low-dose ilo- 
prost, had a total relief of rest pain without analgesics. 
Also, the incidence of major amputation during the 8- 
month study period in the iloprost group was reduced 
after intravenous iloprost (6% vs. 18% in the aspirin 
group) as after low-dose or high-dose of oral iloprost 
(5% and 4% vs. 9% in the placebo group). 
In a pilot open trial in TAO patients it was found 
that 100 gg and 200 gg oral iloprost wice daily result in 
peak plasma levels of 102-155 pg/ml and 177-496 pg/ 
ml. 1° After treatment with low-dose iloprost mean 
plasma levels in thedosing interval accounted for 
83-159 pg/ml; whereas high-dose intake led to iloprost 
levels of 104-242 pg/ml, revealing an acceptable vel 
of compliance. The latter steady state plasma con- 
centration was also obtained in TAO patients with an 
intravenous infusion of 2 ng/kg/min ~°, a dose that has 
been used most frequently in a variety of clinical 
conditions. ~4-16 The incidence of adverse ffects during 
the 8-week treatment period was 25% higher in the 
high-dose than in the low-dose iloprost group. How- 
ever, the difference in adverse ffects between the low- 
dose iloprost and placebo group was minute, viz. 43% 
and 38%, respectively. 
While both oral iloprost doses were shown to be 
safe, the lower dose of 100 gg twice daily was found 
to be the best dose concerning tolerability as well as 
efficacy. The finding that the higher dose of iloprost 
appeared to be less effective than the lower dose 
during follow-up was unexpected and puzzling. No 
evident reasons from the data could be identified. It 
is known that prolonged administration of a high- 
dose of iloprost can decrease the epoprostenol receptor 
binding capacity by 40% due to receptor down-regu- 
lationY Whether this could explain the limited clinical 
effect of 200 gg oral iloprost bid during follow-up in 
the present rial is a matter of conjecture, since an 
intermittent dose regimen was applied. Alternatively, 
the stronger vasodilation induced by the higher ilo- 
prost dose, evident by the considerably higher in- 
cidence of headache and flushing, could have 
counteracted beneficial effects mediated through in- 
hibition of platelet activation, e.g. by causing steal 
effects directing blood flow to muscle tissue at the 
expense of decreased blood circulation of the skin in 
the ischaemic area. Also, when Beraprost, another 
orally active prostacyclin, was investigated, the highest 
dose (180 gg daily) was less effective than lower doses 
(120 ~tg and 60 gg daily) in reducing the pain-free 
walking distance. In some patients with angina pec- 
toris, exercise-induced angina was reported to have 
aggravated during infusion of higher doses of iloprost 
(4-6 ng/kg/min). ~s These findings were explained by 
occurrence of steal phenomena. Caspary et al. 19 re- 
ported in PAOD patients an increase in TcPO2, capillary 
density and blood cell velocity after intravenous in- 
fusion of iloprost. The effects were of variable intensity 
and occurred at varying doses, some appeared already 
at low doses of iloprost (0.25-0.5ng/kg/min) and 
decreased as the dose was increased, while others 
were found only at the highest iloprost dose of 2.0 ng/ 
kg/min. 
Conclusions 
Oral iloprost, 100 gg and 200 gg administered twice 
daily for 8 weeks to patients with TAO, was safe. Low- 
dose iloprost was significantly more effective than 
placebo for total relief of rest pain without need of 
analgesics and for a combined endpoint, at month 6/ 
end of follow-up, whilst both iloprost doses showed 
no significant effects vs. placebo on total healing of 
the most important lesion (primary endpoint). Reasons 
for lack of significant effects with high-dose iloprost 
remain unexplained. 
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